5/10/2022 4:49:20 PM
Wedbush Is Increasing Nuvation Bio Inc. (NUVB) FY23 Estimate To -0.93 From -1.27
5/10/2022 4:49:08 PM
Wedbush Is Increasing Nuvation Bio Inc. (NUVB) Q4 23 Estimate To -0.26 From -0.36
5/10/2022 4:48:56 PM
Wedbush Is Raising Nuvation Bio Inc. (NUVB) Q3 23 Estimate To -0.24 From -0.33
5/10/2022 4:48:45 PM
Wedbush Is Increasing Nuvation Bio Inc. (NUVB) Q2 23 Estimate To -0.23 From -0.30
5/10/2022 4:48:33 PM
Wedbush Is Raising Nuvation Bio Inc. (NUVB) Q1 23 Estimate To -0.20 From -0.27
5/10/2022 4:48:16 PM
Wedbush Is Raising Nuvation Bio Inc. (NUVB) FY22 Estimate To -0.54 From -0.73
5/10/2022 4:48:04 PM
Wedbush Is Raising Nuvation Bio Inc. (NUVB) Q4 22 Estimate To -0.17 From -0.23
5/10/2022 4:47:50 PM
Wedbush Is Raising Nuvation Bio Inc. (NUVB) Q3 22 Estimate To -0.15 From -0.20
5/10/2022 4:47:38 PM
Wedbush Is Raising Nuvation Bio Inc. (NUVB) Q2 22 Estimate To -0.12 From -0.16
5/10/2022 4:47:05 PM
Wedbush Reiterates Nuvation Bio Inc. (NUVB) At Outperform With $17 Down From $23 Price Target
3/1/2022 5:05:19 PM
Wedbush Is Lowering Nuvation Bio Inc. (NUVB) FY22 Estimate To -0.73 From -0.66
3/1/2022 5:05:07 PM
Wedbush Is Cutting Nuvation Bio Inc. (NUVB) Q4 22 Estimate To -0.23 From -0.20
3/1/2022 5:04:53 PM
Wedbush Is Cutting Nuvation Bio Inc. (NUVB) Q3 22 Estimate To -0.20 From -0.18
3/1/2022 5:04:40 PM
Wedbush Is Cutting Nuvation Bio Inc. (NUVB) Q2 22 Estimate To -0.16 From -0.15
3/1/2022 5:04:29 PM
Wedbush Is Lowering Nuvation Bio Inc. (NUVB) Q1 22 Estimate To -0.14 From -0.13
3/1/2022 5:04:01 PM
Wedbush Reiterates Nuvation Bio Inc. (NUVB) At Outperform With $23 Price Target
1/20/2022 7:08:52 AM
Nuvation Bio Announces FDA Clearance Of IND Application For NUV-868 For Advanced Solid Tumors
12/15/2021 7:05:49 AM
Nuvation Bio Receives FDA Fast Track Designation For NUV-422 For The Treatment Of High-Grade Gliomas,